The effects of 3-month atorvastatin therapy on arterial inflammation, calcification, abdominal adipose tissue and circulating biomarkers

Wu, Yen‐Wen; Kao, Hsien‐Li; Huang, Chi-Lun; Chen, Ming-Fong; Lin, Lian‐Yu; Wang, Yi‐Chih; Lin, Yen‐Hung; Lin, Hung‐Ju; Tzen, Kai-Yuan; Yen, Ruoh‐Fang; Chi, Yu-Chiao; Huang, Pei‐Hsin; Yang, Wei‐Shiung

doi:10.1007/s00259-011-1994-7

Cited by 93 publications

(80 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The visceral adipose tissue (VAT) area and subcutaneous adipose tissue (SAT) area were determined by automatic planimetry at the umbilical level. The intra- and inter-reader reproducibility was high for the SAT and VAT measurements in our laboratory (inter-reader and intra-reader comparisons, all r ≥0.98, p <0.0001) [21].…”

Section: Methodsmentioning

confidence: 68%

Evaluation of Circulating Adipokines and Abdominal Obesity as Predictors of Significant Myocardial Ischemia Using Gated Single-Photon Emission Computed Tomography

Hung

Huang

et al. 2014

PLoS ONE

Self Cite

View full text Add to dashboard Cite

ObjectiveCoronary artery disease (CAD) is associated with abdominal obesity and metabolic syndrome. Adipocytes secrete adipokines, including the newly discovered adipocyte fatty acid binding protein (A-FABP) and chemerin. Adipokines contribute to the pathogenesis of CAD. In patients with CAD, the presence of significant ischemia predicts adverse outcomes. It is unknown whether adipokines can be better predictors of the presence of significant myocardial ischemia than conventional risk factors. This study aimed to compare adipokines with clinical risk factors and abdominal obesity as predictive factors for significant myocardial ischemia.MethodsOne hundred and ninety-six adults with suspected, but unproven, CAD were consecutively enrolled. The main measures were clinical and biochemical parameters and stress myocardial perfusion imaging with gated myocardial perfusion single-photon emission computed tomography (SPECT), with computed tomography (CT) attenuation correction. The abdominal visceral fat area was examined using a hybrid SPECT/CT scanner. Serum levels of high-sensitivity C-reactive protein (hs-CRP) and adipokines (adiponectin, A-FABP, and chemerin) were evaluated.ResultsA-FABP levels correlated significantly with adiponectin, hs-CRP, body mass index, waist circumference, and visceral fat area. A-FABP was significantly associated with metabolic syndrome (OR 3.2, 95% CI 1.6–6.4, p = 0.001), significant myocardial ischemia (OR 1.9, 95% CI 1.0–3.4, p = 0.05), and stress lung-to-heart ratio (β = 0.03, p = 0.03) on SPECT. Chemerin was significantly associated with serum triglyceride levels but not with metabolic syndrome, significant ischemia, or stress lung-to-heart ratio on SPECT. A-FABP was better at detecting significant inducible ischemia than other biomarkers, although this was a modest improvement (area under ROC curve 0.579, 95% CI 0.46–0.69).ConclusionsSerum A-FABP concentrations correlate significantly with visceral fat area, metabolic syndrome, and predicted significant myocardial ischemia on SPECT. This may help to more accurately assess CAD risk, especially in patients with metabolic syndrome.

show abstract

Section: Methodsmentioning

confidence: 68%

Evaluation of Circulating Adipokines and Abdominal Obesity as Predictors of Significant Myocardial Ischemia Using Gated Single-Photon Emission Computed Tomography

Hung

Huang

et al. 2014

PLoS ONE

Self Cite

View full text Add to dashboard Cite

show abstract

“…Vascular inflammation and atherosclerotic plaque burden have been demonstrated to be related in previous studies [26]. There have been several types of drugs tested with PET/CT where it has demonstrated reductions in vascular inflammation compared with placebo, including statins and TZDs [17,26,34]. However, our trial is the first to use PET/CT in a patient group with recent ACS.…”

Section: Treatment Effectsmentioning

confidence: 74%

A phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndrome

et al. 2015

View full text Add to dashboard Cite

“…[144][145][146][147] La señal vascular cuantitativa de PET FDG ha sido ampliamente utilizada como un objetivo subrogado para probar los efectos de drogas antiinflamatorias en los estudios clínicos. [148][149][150][151][152][153][154][155] La PET con FDG se está usando activamente como un objetivo subrogado en muchos estudios en curso de ateroesclerosis. Más recientemente, otros agentes de imágenes novedosos dirigidos se han utilizado con PET para caracterizar la inflamación 134,156-160 y otros aspectos de la biología de la placa que incluyen la neoangiogénesis 161 y microcalcificación, 162 y también en complicaciones de la ateroesclerosis 163 en animales experimentales y seres humanos.…”

Section: Imágenes De Infarto De Miocardiounclassified

The Future of Cardiovascular Imaging

2016

View full text Add to dashboard Cite

O ver the past 2 decades, we have witnessed an explosive expansion in the armamentarium of noninvasive and invasive imaging technologies capable of providing detailed information about the structure and function of the heart and vasculature. Many of these technologies are integrative (eg, positron emission tomography and computed tomography, positron emission tomography and MRI), thereby compounding the unique strengths of the component technologies to achieve unprecedented improvements to our ability to diagnose disease, improve patient care, and advance biomedical research. In addition, the miniaturization of imaging devices with dramatic increases in sensitivity and spatial resolution, coupled with the development of quantitative molecular imaging approaches for evaluating physiology and pathobiology at the cellular and molecular levels, provides a unique platform for a new era in diagnostic imaging. The crucial role of imaging in early phenotyping of disease, risk assessment, and management guidance is expanding rapidly in ways previously thought unrealistic.Along with clinical, molecular, and genomewide association studies, structural and functional quantitative imaging already plays a critical role in phenotyping cardiovascular disease. Unique strengths of imaging phenotyping include its ability to provide precise, organ-specific anatomic localization and quantification of disease traits, to demonstrate and quantify involvement of other organs in cardiac disease, to provide an opportunity to investigate the time course of disease-specific molecular events in vivo, and to track their response to therapy. In so doing, quantitative structural and functional imaging can provide a nuanced description of disease burden (eg, atherosclerosis, myocarditis), disease subtypes (eg, amyloidosis), and, importantly, the relationship between the specific phenotype and outcomes, thereby informing treatment strategies and allowing more personalized approaches to patient management.Our objectives for this article are to (1) provide a viewpoint regarding the evolving role of cardiovascular imaging in biomedical research and clinical practice, (2) discuss the challenges associated with clinical translation of imaging innovations and the opportunities for multimodality imaging in the changing paradigm of value-based medicine, and (3) briefly outline future challenges and opportunities including the requirements for training future generations of imaging scientists and clinical specialists. Unlike traditional reviews that provide a detailed discussion of the role of 1 or more imaging modalities in cardiovascular (CV) disease, our discussion will focus on the potential role of imaging in what we believe are key areas of the translational highway with specific examples on how structural and functional imaging may contribute to scientific discovery, diagnosis, risk stratification, and patient management in each of those areas. Redefining the Role of Imaging Across the Continuum of Biomedical Research and Clinical Practice Translati...

show abstract

The effects of 3-month atorvastatin therapy on arterial inflammation, calcification, abdominal adipose tissue and circulating biomarkers

Abstract: The medium dose of atorvastatin over a 12-week period resulted in a significant reduction of arterial inflammation as well as various circulating biomarkers.

Cited by 93 publications

References 38 publications

Evaluation of Circulating Adipokines and Abdominal Obesity as Predictors of Significant Myocardial Ischemia Using Gated Single-Photon Emission Computed Tomography

Evaluation of Circulating Adipokines and Abdominal Obesity as Predictors of Significant Myocardial Ischemia Using Gated Single-Photon Emission Computed Tomography

A phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndrome

The Future of Cardiovascular Imaging

Contact Info

Product

Resources

About